TRESEPOCAS: Respiratory Therapy in COPD Exacerbations

Sponsor
Parc de Salut Mar (Other)
Overall Status
Completed
CT.gov ID
NCT02125747
Collaborator
(none)
35
1
2
11
3.2

Study Details

Study Description

Brief Summary

The purpose of this study is to determine effectiveness, feasibility and safety/tolerance of Respiratory Therapy in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease.

Condition or Disease Intervention/Treatment Phase
  • Other: No Respiratory Therapy
  • Other: Respiratory Therapy
N/A

Detailed Description

Acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) is defined as an event in the natural course of the disease characterized by a change in the patient's usual symptoms (dyspnea, cough and/or sputum) that may not be explained by the daily variations and requires a change in regular medication.

Because AE-COPD result in impairment of both pulmonary and respiratory muscle functions, as well as an increasing impact on costs, priority should be given to interventions to slow the progression of the disease, prevention of exacerbations and reduce the risk of comorbidity.

Chest physiotherapy is often used in hospitalized patients with AE-COPD with the aim of favoring the removal of secretions and thus to improve the ventilation perfusion (V/Q), and therefore the function lung. The limited scientific evidence has determined that their use is controversial and not routinely recommended in clinical practice guidelines. Current clinical guidelines in the treatment of COPD are unable to rule on the application of respiratory therapy during exacerbations, since there is little scientific evidence of its benefits in the short and long term.

Study Design

Study Type:
Interventional
Actual Enrollment :
35 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Respiratory Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Study Start Date :
Dec 1, 2011
Actual Primary Completion Date :
May 1, 2012
Actual Study Completion Date :
Nov 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Other: No Respiratory Therapy

Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment.

Other: No Respiratory Therapy
Patients received conventional treatment.

Experimental: Respiratory therapy

Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment and Respiratory Therapy

Other: Respiratory Therapy
Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area. The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions. Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period.

Outcome Measures

Primary Outcome Measures

  1. Respiratory muscle strength [Participants will be followed for the duration of hospital stay, an expected average of 10 days]

    Respiratory muscle strength is assessed through maximal inspiratory pressures (MIP) and maximal expiratory pressures (MEP) using a pressure transducer connected to a digital register system. The MIP is measured at mouth during a maximum effort from residual volume against occluded airway. To determine the MEP, patients performed a maximum expiratory effort from total lung capacity in the face of the occluded airway.

Secondary Outcome Measures

  1. Measure of safety and tolerability [Participants will be followed for the duration of hospital stay, an expected average of 10 days]

    Presence of complications and patients' satisfaction

  2. Adverse events as a measure of safety and tolerability [One year after hospital discharge]

    Monitoring of health status and possible complications one year after discharge

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Hospitalized patients with acute exacerbation of COPD.

Inclusion Criteria:
  • age over 18 years,

  • hospitalized patients and

  • acute exacerbation of COPD.

Exclusion Criteria:
  • Previous history of any chronic respiratory disease and

  • not to have performed any kind of general or respiratory training in the previous 3 months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Departments of Respiratory Medicine and Rehabilitation. Parc de Salut Mar, Hospital del Mar Barcelona Spain 08003

Sponsors and Collaborators

  • Parc de Salut Mar

Investigators

  • Study Director: Mauricio Orozco-Levi, MD, PhD, Biomedical Research Network for Respiratory Diseases (CIBERES), ISCIII, Ministerio de Ciencia y Tecnología, Spain; Respiratory Department, Hospital del Mar, Spain; Respiratory Department, Centro de Investigaciones, Fundación Cardiovascular de Colombia

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Esther Marco Navarro, PhD, Parc de Salut Mar
ClinicalTrials.gov Identifier:
NCT02125747
Other Study ID Numbers:
  • PSM/RHB/CR/05
First Posted:
Apr 29, 2014
Last Update Posted:
Jan 12, 2017
Last Verified:
Apr 1, 2015
Keywords provided by Esther Marco Navarro, PhD, Parc de Salut Mar
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 12, 2017